Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: The relationship to patient age

Journal of Urology

Volumn 170, Issue 5, 2003, Pages 1864-1867

  Critz, Frank A ^a,c   Williams, W Hamilton ^a   Levinson, A Keith ^b   Benton, James B ^a   Schnell, Frederick J ^a   Holladay, Clinton T ^a   Shrake, Philip D ^a  

^a Radiotherapy Clinics of Georgia   (United States)

^b Georgia Urology   (United States)

^c Radiotherapy Clinics of Georgia   (United States)

Author keywords

Brachytherapy; Prostate specific antigen; Radiotherapy

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

EID: 0141954161     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000091644.41330.2a     Document Type: Article

References (8)

1. Critz, F. A., Williams, W. H., Benton, J. B., Levinson, A. K., Holladay, C. T. and Holladay, D. A.: Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol, 163: 1085, 2000
2. Cavanagh, W., Blasko, J. C., Grimm, P. D. and Sylvester, J. E.: Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. Semin Urol Oncol, 18: 160, 2000
3. Hanlon, A. L., Pinover, W. H., Horwitz, E. M. and Hanks, G. E.: Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys, 50: 845, 2001
4. Crook, J. M., Perry, G. A., Robertson, S. and Esche, B. A.: Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology, 45: 624, 1995
5. Smathers, S., Wallner, K., Sprouse, J. and True, L.: Temporary PSA rises and repeat prostate biopsies after brachytherapy. Int J Radiat Oncol Biol Phys, 50: 1207, 2001
6. Critz, F. A.: A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol, 167: 1310, 2002
7. Critz, F. A.: Time to achieve prostate specific antigen nadir 0.2 ng./ml. following simultaneous irradiation of prostate cancer. J Urol, 168: 2434, 2002
8. Stenner, J., Holthaus, K., Mackenzie, S. H. and Crawford, E. D.: The effect of ejaculation on prostate-specific antigen in a prostate cancer-screening population. Urology, 51: 455, 1998